HS-1793, a resveratrol analogue, induces cell cycle arrest and apoptotic cell death in human breast cancer cells

Kim,Jin-Ah; Kim,Dong Hwan; Hossain,Mohammad Akbar; Kim,Min Young; Sung,Bokyung; Yoon,Jeong-Hyun; Suh,Hongsuk; Jeong,Tae Cheon; Chung,Hae Young; Kim,Nam Deuk

doi:10.3892/ijo.2013.2207

HS-1793, a resveratrol analogue, induces cell cycle arrest and apoptotic cell death in human breast cancer cells

Authors:
- Jin-Ah Kim
- Dong Hwan Kim
- Mohammad Akbar Hossain
- Min Young Kim
- Bokyung Sung
- Jeong-Hyun Yoon
- Hongsuk Suh
- Tae Cheon Jeong
- Hae Young Chung
- Nam Deuk Kim
View Affiliations

Affiliations: Department of Pharmacy, Molecular Inflammation Research Center for Aging Intervention, Pusan National University, Busan 609-735, Republic of Korea, Department of Chemistry and Chemistry Institute for Functional Materials, Pusan National University, Busan 609-735, Republic of Korea, College of Pharmacy, Yeungnam University, Gyeongsan 712-749, Republic of Korea
Published online on: December 5, 2013 https://doi.org/10.3892/ijo.2013.2207
Pages: 473-480

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Resveratrol, a polyphenolic compound, is a naturally occurring phytochemical and is found in a variety of plants, including food such as grapes, berries and peanuts. It has gained much attention for its potential anticancer activity against various types of human cancer. However, the usefulness of resveratrol as a chemotherapeutic agent is limited by its photosensitivity and metabolic instability. In this study the effects of a synthetic analogue of resveratrol, HS-1793, on the proliferation and apoptotic cell death were investigated using MCF-7 (wild-type p53) and MDA-MB-231 (mutant p53) human breast cancer cells. HS-1793 inhibited cell growth and induced apoptotic cell death in a concentration-dependent manner. The induction of apoptosis was determined by morphological changes, cleavage of poly(ADP-ribose) polymerase, alteration of Bax/Bcl-2 expression ratio and caspase activities. Flow cytometric analysis revealed that HS-1793 induced G2/M arrest in the cell cycle progression in both types of cells. Of note, HS-1793 induced p53/p21WAF1/CIP1-dependent apoptosis in MCF-7 cells, whereas it exhibited p53-independent apoptosis in MDA-MB-231 cells. Furthermore, HS-1793 showed more potent anticancer effects in several aspects compared to resveratrol in MCF-7 and MDA-MB-231 cells. Thus, these findings suggest that HS-1793 has potential as a candidate chemotherapeutic agent against human breast cancer.

View Figures

View References

1.	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
2.	DeSantis C, Siegel R, Bandi P and Jemal A: Breast cancer statistics, 2011. CA Cancer J Clin. 61:409–418. 2011. View Article : Google Scholar
3.	Kim HJ, Yang KM, Park YS, et al: The novel resveratrol analogue HS-1793 induces apoptosis via the mitochondrial pathway in murine breast cancer cells. Int J Oncol. 41:1628–1634. 2012.PubMed/NCBI
4.	Baur JA and Sinclair DA: Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 5:493–506. 2006. View Article : Google Scholar : PubMed/NCBI
5.	Marques FZ, Markus MA and Morris BJ: Resveratrol: cellular actions of a potent natural chemical that confers a diversity of health benefits. Int J Biochem Cell Biol. 41:2125–2128. 2009. View Article : Google Scholar : PubMed/NCBI
6.	Khan N, Afaq F and Mukhtar H: Cancer chemoprevention through dietary antioxidants: progress and promise. Antioxid Redox Signal. 10:475–510. 2008. View Article : Google Scholar : PubMed/NCBI
7.	Fulda S and Debatin KM: Resveratrol-mediated sensitisation to TRAIL-induced apoptosis depends on death receptor and mitochondrial signalling. Eur J Cancer. 41:786–798. 2005. View Article : Google Scholar : PubMed/NCBI
8.	Garvin S, Ollinger K and Dabrosin C: Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo. Cancer Lett. 231:113–122. 2006. View Article : Google Scholar : PubMed/NCBI
9.	Jang M, Cai L, Udeani GO, et al: Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science. 275:218–220. 1997. View Article : Google Scholar : PubMed/NCBI
10.	Cai YJ, Wei QY, Fang JG, et al: The 3,4-dihydroxyl groups are important for trans-resveratrol analogs to exhibit enhanced antioxidant and apoptotic activities. Anticancer Res. 24:999–1002. 2004.PubMed/NCBI
11.	Jeong SH, Lee JS, Jeong NY, et al: A novel resveratrol analogue HS-1793 treatment overcomes the resistance conferred by Bcl-2 and is associated with the formation of mature PML nuclear bodies in renal clear cell carcinoma Caki-1 cells. Int J Oncol. 35:1353–1360. 2009.
12.	Jeong MH, Yang KM, Choi YJ, et al: Resveratrol analog, HS-1793 enhance anti-tumor immunity by reducing the CD4⁺CD25⁺ regulatory T cells in FM3A tumor bearing mice. Int Immunopharmacol. 14:328–333. 2012. View Article : Google Scholar : PubMed/NCBI
13.	Jeong NY, Yoon YG, Rho JH, et al: The novel resveratrol analog HS-1793-induced polyploid LNCaP prostate cancer cells are vulnerable to downregulation of Bcl-xL. Int J Oncol. 38:1597–1604. 2011.PubMed/NCBI
14.	Jeong SH, Song IS, Kim HK, et al: An analogue of resveratrol HS-1793 exhibits anticancer activity against MCF-7 cells via inhibition of mitochondrial biogenesis gene expression. Mol Cells. 34:357–365. 2012. View Article : Google Scholar : PubMed/NCBI
15.	Kim DH, Hossain MA, Kim MY, et al: A novel resveratrol analogue, HS-1793, inhibits hypoxia-induced HIF-1alpha and VEGF expression, and migration in human prostate cancer cells. Int J Oncol. 43:1915–1924. 2013.PubMed/NCBI
16.	Ma Z, Molavi O, Haddadi A, Lai R, Gossage RA and Lavasanifar A: Resveratrol analog trans 3,4,5,4'-tetramethoxystilbene (DMU-212) mediates anti-tumor effects via mechanism different from that of resveratrol. Cancer Chemother Pharmacol. 63:27–35. 2008.
17.	Kotha A, Sekharam M, Cilenti L, et al: Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein. Mol Cancer Ther. 5:621–629. 2006. View Article : Google Scholar : PubMed/NCBI
18.	Momand J, Zambetti GP, Olson DC, George D and Levine AJ: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 69:1237–1245. 1992. View Article : Google Scholar : PubMed/NCBI
19.	Honda R, Tanaka H and Yasuda H: Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420:25–27. 1997. View Article : Google Scholar : PubMed/NCBI
20.	Makin G and Dive C: Modulating sensitivity to drug-induced apoptosis: the future for chemotherapy? Breast Cancer Res. 3:150–153. 2001. View Article : Google Scholar : PubMed/NCBI
21.	Wilkinson MG and Millar JB: Control of the eukaryotic cell cycle by MAP kinase signaling pathways. FASEB J. 14:2147–2157. 2000. View Article : Google Scholar : PubMed/NCBI
22.	Bates S, Bonetta L, MacAllan D, et al: CDK6 (PLSTIRE) and CDK4 (PSK-J3) are a distinct subset of the cyclin-dependent kinases that associate with cyclin D1. Oncogene. 9:71–79. 1994.PubMed/NCBI
23.	Ellis M, Chew YP, Fallis L, et al: Degradation of p27(Kip) cdk inhibitor triggered by Kaposi's sarcoma virus cyclin-cdk6 complex. EMBO J. 18:644–653. 1999.PubMed/NCBI
24.	Taylor WR and Stark GR: Regulation of the G2/M transition by p53. Oncogene. 20:1803–1815. 2001. View Article : Google Scholar : PubMed/NCBI
25.	Bennett M, Macdonald K, Chan SW, Luzio JP, Simari R and Weissberg P: Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. Science. 282:290–293. 1998. View Article : Google Scholar : PubMed/NCBI
26.	Earnshaw WC, Martins LM and Kaufmann SH: Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem. 68:383–424. 1999. View Article : Google Scholar : PubMed/NCBI
27.	Filomeni G, Graziani I, Rotilio G and Ciriolo MR: trans-Resveratrol induces apoptosis in human breast cancer cells MCF-7 by the activation of MAP kinases pathways. Genes Nutr. 2:295–305. 2007. View Article : Google Scholar : PubMed/NCBI